Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

864 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.
Ishiba H, Fujii H, Kamada Y, Sumida Y, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Fukushima H, Miyoshi E, Aishima S, Itoh Y, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Ishiba H, et al. Among authors: shima t. Hepatol Commun. 2024 Dec 11;9(1):e0563. doi: 10.1097/HC9.0000000000000563. eCollection 2025 Jan 1. Hepatol Commun. 2024. PMID: 39670882 Free PMC article.
Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes.
Ishiba H, Sumida Y, Seko Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Mori K, Kanemasa K, Shimada K, Imajo K, Yamaguchi K, Kawaguchi T, Nakajima A, Chayama K, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of NAFLD. Ishiba H, et al. Among authors: shima t. Hepatol Commun. 2020 Nov 16;5(4):559-572. doi: 10.1002/hep4.1637. eCollection 2021 Apr. Hepatol Commun. 2020. PMID: 33860115 Free PMC article.
Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study.
Seko Y, Takahashi H, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Seko Y, et al. Among authors: shima t. Hepatol Res. 2023 Apr;53(4):312-321. doi: 10.1111/hepr.13871. Epub 2023 Jan 10. Hepatol Res. 2023. PMID: 36524984
Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.
Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, Ikegami T, Fujii H, Toyoda H, Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanoue T, Nakajima A, Takahashi H; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Oeda S, et al. Among authors: shima t. Hepatol Res. 2023 Jun;53(6):489-496. doi: 10.1111/hepr.13890. Epub 2023 Mar 7. Hepatol Res. 2023. PMID: 36807720
Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
Arai T, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Arai T, et al. Among authors: shima t. Clin Gastroenterol Hepatol. 2024 Apr;22(4):789-797.e8. doi: 10.1016/j.cgh.2023.11.022. Epub 2023 Dec 2. Clin Gastroenterol Hepatol. 2024. PMID: 38048934
Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Yasui K, et al. Among authors: shima t. Clin Gastroenterol Hepatol. 2011 May;9(5):428-33; quiz e50. doi: 10.1016/j.cgh.2011.01.023. Epub 2011 Feb 12. Clin Gastroenterol Hepatol. 2011. PMID: 21320639
Hepatic steatosis in chronic hepatitis C patients infected with genotype 2 is associated with insulin resistance, hepatic fibrosis and affects cumulative positivity of serum hepatitis C virus RNA in peginterferon and ribavirin combination therapy.
Itoh Y, Nishimura T, Yamaguchi K, Yokomizo C, Fujii H, Minami M, Nagao Y, Sumida Y, Hashimoto H, Umemura A, Shima T, Okanoue T, Yoshikawa T. Itoh Y, et al. Among authors: shima t. Hepatol Res. 2011 Dec;41(12):1145-52. doi: 10.1111/j.1872-034X.2011.00886.x. Epub 2011 Sep 26. Hepatol Res. 2011. PMID: 21951359
864 results